Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
2008 Base Salaries
On
March 25, 2008, the Compensation Committee of the Board of Directors (the Committee) of Tercica, Inc. (the Company) approved annual base salaries for 2008, effective January 1, 2008, for the following named
executive officers (as defined under applicable securities laws) of the Company in the amounts as set forth in the table below.
|
|
|
Named Executive Officer
|
|
2008 Annual Salary
($)
|
Ajay Bansal
Executive Vice President and Chief Financial Officer
|
|
350,000
|
Stephen N. Rosenfield
Executive Vice President of Legal Affairs, General Counsel and Secretary
|
|
345,000
|
Thorsten von Stein, M.D., Ph.D.
Chief Medical Officer and Senior Vice President of Clinical and Regulatory Affairs
|
|
340,000
|
Andrew J. Grethlein, Ph.D.
Senior Vice President, Pharmaceutical Operations
|
|
310,000
|
Restricted Stock Unit Awards and Stock Option Awards
On March 25, 2008, as part of the Companys annual equity compensation grant process, the Committee granted restricted stock unit awards
(RSUs) to certain of the Companys employees, including to the named executive officers listed in the table above, under the Companys 2004 Stock Plan, as amended (the Plan). On February 26, 2008, the Board of
Directors of the Company (the Board) amended the terms of the Plan to provide for the award of RSUs. Prior to such amendment, the Plan provided for the grant of restricted stock awards but not RSUs. The RSUs will be evidenced by a
Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement (together, the RSU Agreement), which, together with the Plan, set forth the terms and conditions of the RSUs. Under the Plan and the applicable RSU Agreement, each
RSU represents a right to receive one share of the Companys Common Stock (subject to adjustment for certain specified changes in the capital structure of the Company) upon the completion of a specified period of continued service. On
March 25, 2008, the Committee also granted stock options under the Plan to certain of the Companys employees, including to the named executive officers listed in the table above, which stock options carry an exercise price of $6.13 per
share, the fair market value of the Companys common stock on the date of grant, and have a term of ten years.
The number of RSUs and
the number of shares subject to stock options granted to the named executive officers listed in the table above on March 25, 2008 are set forth in the table below, along with a brief description of the vesting conditions applicable to such RSUs
and stock option grants.
|
|
|
|
|
Named Executive Officer
|
|
Number of
RSUs
(#)(1)
|
|
Number of
Shares Subject
to Stock
Options
(#)(2)
|
Ajay Bansal
Executive Vice President and Chief Financial Officer
|
|
14,000
|
|
57,000
|
Stephen N. Rosenfield
Executive Vice President of Legal Affairs, General Counsel and Secretary
|
|
13,500
|
|
55,500
|
Thorsten von Stein, M.D., Ph.D.
Chief Medical Officer and Senior Vice President of Clinical and Regulatory Affairs
|
|
13,500
|
|
55,500
|
Andrew J. Grethlein, Ph.D.
Senior Vice President, Pharmaceutical Operations
|
|
13,500
|
|
55,500
|
(1)
|
25% of the RSUs will vest each year on the anniversary of the grant date, subject to the individuals continued service through each such date, so that the award is fully
vested on the fourth anniversary of the grant date. The vesting of the RSUs is subject to acceleration as provided in each named executive officers employment agreement with the Company.
|
(2)
|
25% of the shares subject to each stock option will vest on the anniversary of the grant date, subject to the
individuals continued service through such date, and 1/48
th
of the shares subject to each stock option will vest on a monthly basis thereafter
subject to continued service, so that each stock option will be fully vested on the fourth anniversary of the date of grant. The vesting of the stock options is subject to acceleration as provided in each named executive officers employment
agreement with the Company.
|
The foregoing is only a brief description of the material terms of the RSUs and the stock
options granted to the named executive officers, does not purport to be complete and is qualified in its entirety by reference to the Plan, the form of RSU Agreement under the Plan and the form of Stock Option Agreement under the Plan. A copy of the
form of Stock Option Agreement under the Plan was previously filed as Exhibit 10.3B to the Companys Registration Statement on Form S-1 and amendments thereto, declared effective on March 16, 2004. The Plan, as amended, and the form of RSU
Agreement under the Plan will be filed as exhibits to the Companys Quarterly Report on Form 10-Q for the quarter ending March 31, 2008.
Amendment to Executive Employment Agreements
On March 25, 2008, the Committee also approved an amendment to
each of the employment agreements the named executive officers listed in the tables above previously entered into with the Company to provide that the vesting of the RSUs will be subject to the same change of control vesting acceleration provisions
as are applicable to stock options granted to the named executive officers (the Employment Agreement Amendment). Accordingly, in the case of each of Mr. Bansal and Mr. Rosenfield, the Employment Agreement Amendment provides
that in the event that such named executive officer is terminated without cause or terminates his own employment for good reason within 12 months following a change of control, as these terms are defined in such named executive officers
employment agreement, the vesting of all of such named executive officers RSUs will be accelerated in full. In the case of each of Dr. von Stein and Dr. Grethlein, the Employment Agreement Amendment provides that in the event that
such named executive officer is terminated without cause or terminates his own employment for good reason within 12 months following a change of control, as these terms are defined in their respective employment agreements, the vesting of such named
executive officers RSUs will be accelerated such that 50% of such named executive officers unvested RSUs will immediately vest in full.
The foregoing is only a brief description of the material terms of the Employment Agreement Amendment, does not purport to be complete and is qualified in its entirety by reference to the form of Employment Agreement Amendment that will be
filed as an exhibit to the Companys Quarterly Report on Form 10-Q for the quarter ending March 31, 2008.